amino acid treatment overview

72 Pages·2006·6.58 MB·English

_I
---- 1-
(cid:127) (cid:127) (cid:127) (cid:127)
I
amino
acid
treatment
overview
NEURO
RESEARCH
Expanding the frontiers of knowledge with n Neurotransmitter Technical Support
The Phase 3 Response NeuroResearch: 877-626-2220
™

www.NeuroAssist.com
See page 5
NeuroResearch is dedicated to providing category I
continuing medical education to physicians and category I
continuing education units to psychologists.
www.NeuroSupport.com
-1 I
NeuroResearch Catalog Dec 20.ind1 1 12/20/06 12:44:49 PM
i -
I
I
_I .
(cid:127) (cid:127) (cid:127) (cid:127)
A quick
Low Neurotransmitters in the Body Cause Other Diseases
overview
—Bulimia
—Parkinsonism
Obesity Type II Diabetes —Obesity
—Anorexia
—Depression
—Decreased Life Expectancy —Decreased Life Expectancy
—Anxiety
—Diabetes —Increased Infections
—Panic Attacks
—Heart Disease —Diabetic Neuropathy
—Migraine Headaches
—Increased Rate of Stroke —Kidney Failure
—Tension Headaches
—Sleep Apnea —Macular Degeneration (blind)
—Premenstrual Syndrome (PMS)
—Knee Problems —Heart Disease
—Menopausal Symptoms
—Back Problems —Foot Ulcers
—Obsessive Compulsive Disorder (OCD)
—Increased Rehabilitation Time —Vascular Disease
—Impulsivity
—Increased Rate of Injuries —Therapeutic Amputations
—Obsessionality
—Increases in Gall Stones —Disability
—Insomnia
—Female Fertility Problems —Increased Rate of Stroke
—Inappropriate Aggression
—Gynecologic Irregularities —Impotence
—Inappropriate Anger
—Gouty Arthritis
—Psychotic Illness
1 —High Blood Pressure High Blood Pressure —Fibromyalgia
—Hiatal Hernia
and High Cholesterol —Chronic Fatigue Syndrome
—High Cholesterol
—Adrenal Fatigue/Burnout
—Increased Lung Infections
—Hyperactivity
—Increases in Gastric Ulcers
—Decreased Life Expectancy —ADHD/ADD
—Chronic Pain
—Heart Disease —Hormone Dysfunction
—Fibromyalgia
—Stroke —Adrenal Dysfunction
—Myoclonus
—Kidney Failure —Dementia
—Vascular Disease —Alzheimer’s Disease
—Ischemia —Traumatic Brain Injury
Increases the Risk of Cancer
—Phobias
—Chronic Pain
—Increased Colon Cancer
“Most patients have 3 or more —Nocturnal Myoclonus
—Increased Uterine Cancer
neurotransmitter dysfunction —Irritable Bowel Syndrome
—Increased Breast Cancer
diseases active at one time.” —Crohn’s Disease
—Ulcerative Colitis
Real Treatment: Natural treatment that corrects problems without —Cognitive Deterioration
—Organ System Dysfunction
the risks of side effects from prescription drugs.
—Management of Chronic Stress
Weight Loss: As indicated in the above list, obesity causes many problems —Cortisol Dysfunction
—Restless Leg Syndrome
This is not a comprehensive list. Catecholamine and serotonin amino acid precursors have a positive impact
on virtually all disease states caused by or associated with serotonin and/or catecholamine dysfunction.
NeuroResearch Catalog Dec 20.ind2 2 12/20/06 12:45:11 PM
_ I . (cid:127) (cid:127) (cid:127) (cid:127) ----r---r--..,......... I I _
A quick
Specific Master Neurotransmitters Implicated in Disease
overview
Norepinephrine can take 2 to 6 weeks to stabilize and epinephrine can take 3 to 6 months to stabilize once
serotonin and dopamine levels are in the therapeutic range AND in The Phase 3 Response™. Given the time
it takes for norepinephrine and epinephrine to stabilize, the chart below provides a reasonable explanation
of why some illnesses (i.e. insomnia) can take 2 to 6 weeks for symptoms to improve after serotonin and
dopamine levels are in the therapeutic range and The Phase 3 Response™.
Disease Serotonin Dopamine Norepinephrine Epinephrine
Obesity X X
Depression X X X X
Insomnia X X
ADHD X X X
Migraine Headaches X
Parkinsonism X 
Hormone Imbalance X
Fibromyalgia X X X X
Chronic Fatigue X X X X
Low Cortisol / Low DHEA X
Bulimia / Anorexia X X
Anxiety / Panic Attacks X X X X
PMS X
Obsessive Compulsive Disorder X X X
Aggression X X X
Irritable Bowel / Crohn’s Disease X
Adrenal Dysfunction X
Psychotic Illness X X X X

NeuroResearch Catalog Dec 20.ind2 2 12/20/06 12:45:32 PM
_I .
(cid:127) (cid:127) (cid:127) (cid:127)
Perspective
Applications of NeuroResearch’s
AMINO ACID PROTOCOLS
The NeuroResearch amino acid treat- an effort to find a correlation between
n The amino acid formulas and protocols of NeuroResearch
ment protocols are based upon research urinary master neurotransmitters and are effective in any disease or illness where improper
started in 1995, at the Morgan Park master neurotransmitter related illnesses. levels of serotonin and/or the catecholamines (dopa-
mine, norepinephrine, and epinephrine) have been
Medical Clinic in Duluth, Minnesota. This work resulted in defining the three
implicated.
Our medical doctors began using phases of urinary neurotransmitter
amino acids with prescription drugs in response to amino acid therapy. From n The amino acid formulas and protocols of NeuroResearch,
when given in combination with prescription drugs that
response to the problem of weight loss these findings, it was observed that
utilize serotonin and/or catecholamines, ensure that drugs
prescription drugs developing tachyphy- urinary neurotransmitters in the thera-
targeting the master neurotransmitters function at optimal
laxis (quit working). Our research quickly peutic range and in The Phase 3 efficacy.
turned to the bigger picture of maintain- Response™ correlate highly with the
n The NeuroResearch database contains documented
ing the effectiveness of prescription resolution of disease symptoms and an treatment history over 1 million patient days of treatment.
drugs used to treat diseases related to optimal feeling of wellness. Out of this collection of data, we have documented that the
amino acid formulas are safe with ALL prescription drugs.
the master neurotransmitters (serotonin Today, NeuroResearch’s approach is
and/or catecholamines - dopamine, being used by over 800 clinics in the n The amino acid formulas and protocols of
 norepinephrine, and epinephrine). United States and Canada. This approach NeuroResearch are effective without prescription
drugs for the treatment of neurotransmitter
By 1998, the problem of maintaining the represents the first real alternative to
dysfunction diseases and illnesses involving the
effectiveness of prescription drugs used prescription drugs in the treatment of master neurotransmitters.
to treat diseases related to the master neurotransmitter dysfunction diseases
n Treatment approaches of amino acid protocols include:
neurotransmitters had been solved with without the side effects and problems
n Attempting to use amino acids to treat patients
the use of amino acids. associated with prescribed drugs. without training (least effective).
In 1999, an amino acid formulation was Since defining The Phase 3 Response™
n Using properly balanced amino acids formulas
perfected that allowed the treatment of in conjunction with the therapeutic range, without proper training in the treatment of patients.
master neurotransmitter related illnesses we have turned our attention to further n Using properly balanced amino acid formulas in
without the use of prescription drugs. exploring the many potential applications conjunction with laboratory testing to optimize
individual and group outcomes.
In 2001, NeuroResearch began working of our findings and technology.
with urinary neurotransmitter testing in n Amino acid therapy is not new. NeuroResearch’s
approach is innovative because it uses the clinical
database to guide treatment to previously unknown
Patent application of technology covered in this manual is under world wide PCT patent filing and under the following
levels of efficacy in the treatment of master neu-
U.S. Patents issued and Published Patent Applications in place as of October 15, 2006. (Unpublished patent applica-
tions are not listed here.) U.S. Patents 6,384,088, 6,403,657, 6,548,551, 6,660,777, 6,759,437. rotransmitter dysfunction diseases.
U.S. Patent Applications (Published) 20020025972, 20020040054, 20020065311, 20020072537, 20020094969,
20030181509, 20040101575, 20040229285, 20050065190, 20050233008, 20060110325, 20060135567, 20060178423
NeuroResearch Catalog Dec 20.ind3 3 12/20/06 12:45:47 PM
_I .
(cid:127) (cid:127) (cid:127) (cid:127)
Introduction 31 ..... GI Upset upon Starting Amino Acids
32 ..... GI Upset, Carbohydrate Intolerance
1......Master Neurotransmitter Diseases
33 ..... GI Upset Due to Cysteine and Paradoxical Reactions
2......Master Neurotransmitter Disease Associations
34 ..... Paradoxical Reactions, Page 2
3......Overview
35 ..... Heartburn, Dizziness, and Hypersomnolence
4......Table of Contents
Neurotransmitter Testing Laboratory Considerations
Continuing Medical Education
36 ..... Introduction to Urinary Neurotransmitter Testing
5 ..... Continuing Medical Education Overview
37 ..... Baseline Urinary Neurotransmitter Testing
6 ..... The Need for Education
38 ..... Urinary Neurotransmitters, The Source
Amino Acid Treatment Discussion 39 ..... Phases of Urinary Neurotransmitter Response, Part 1
7 ..... How to Obtain Optimal Results 40 ..... Phases of Urinary Neurotransmitter Response, Part 2
8 ..... The On/Off Effect of Amino Acid 41 ..... Neurotransmitter Testing Overview
9 ..... Amino Acid Dosing Protocols 42 ..... Neurotransmitter Therapeutic Ranges and Treatment Considerations
10 ..... Amino Acid Treatment Considerations 43 ..... Resolution of Symptoms and Phase of Response
11 ..... The Three Approaches to Amino Acid Therapy 44 ..... Neurotransmitter Systemic and Urinary Diurnal Variation
12 ..... Why Using Plain 5-HTP is not Advised 45 ..... Integrating Neurotransmitter Testing Into Treatment
13 ..... Pitfalls of Amino Acid Dosing Considerations 46 ..... More Urinary Neurotransmitter Testing Considerations
14 ..... Group Amino Acid Dosing Considerations 47 ..... Proper Perspective on Lab Testing and Testing Stats, Part 1
15 ..... The Tyrosine Base, Page 1 48 ..... Testing Stats, Part 2
16 ..... The Tyrosine Base, Page 2 49 ..... Balancing Serotonin and Dopamine Precursors
17 ..... Expectations of Treatment 50 ..... Lab Examples, Part 1 
51 ..... Lab Examples, Part 2
Treating Individual Diseases
52 ..... Lab Examples, Part 3
18 ..... Insomnia/Hypersomnolence 53 ..... The Tip of the Iceberg, Part 1
19 ..... Depression, Page 1 54 ..... The Tip of the Iceberg, Part 2
20 ..... Depression, Page 2
Other Considerations Involving the Master Neurotransmitters
21 ..... Parkinsonism
22 ..... Parkinsonism and ADHD/ADD 55 ..... How Drugs Deplete Neurotransmitters
23 ..... Pediatric Amino Acid Dosing and ADHD 56 ..... Keeping Drugs Functioning Optimally
24 ..... ADHD Drugs 57 ..... N-Acetyl Tyrosine
25 ..... Migraine Headaches, Chronic Pain, and 58 ..... N-Acetyl Cysteine (NAC)
Anti-Aging Applications 59 ..... Beta-Phenylethylamine (PEA)
26 ..... Hormone and Adrenal Burnout 60 ..... GABA
27 ..... Obesity Treatment Overview, Page 1 61 ..... Prioritizing Treatment
28 ..... Obesity Treatment Overview, Page 2 62 ..... Cortisol
29 ..... OCD, Bulimia, and Anorexia 63 ..... Hormones
64 ..... Melatonin and the Minor Neurotransmitters
Side Effects, Incidence and Management
65 ..... Obesity: Other Treatment Modalities
30 ..... Incidence of Side Effects and Management of
66-69.... Bibliography
Prescription Drug Side Effects
70 ..... New Patient Information Guide
NeuroResearch Catalog Dec 20.ind4 4 12/20/06 12:46:02 PM
_I .
(cid:127) (cid:127) (cid:127) (cid:127)
Perspective Certified for Category I that he/she actually spent in the
activity.
Hours Toward the AMA
These formal scientific education Medical Education Collaborative
seminars are taught by the inven- Recognition Award (MEC) is accredited by the
Continuing MediCal eduCation
tors of “amino acid therapy guided ACCME to provide continuing
by noninvasive laboratory neu- Certification is targeted at medical education for physicians
Course Description
rotransmitter testing in the physicians (MD and DO), nurses, and CEU for psychologists.
treatment of master neurotrans- physician assistants, and psychol- Approved for 9.2 contact hour(s)
This one day multi-disciplinary
mitter dysfunction”. The faculties ogists. In order to receive credit, of continuing education for RNs,
conference is designed to
of these medical education participants must attend at least LPNs, LVNs and NPs.
educate primary care physicians,
seminars are medical doctors who one full session and submit a This program is co-sponsored
psychiatrists, psychologists, and
developed this approach while credit application and evaluation with Medical Education Collab-
allied health professionals on the
caring for patients in their clinical form before leaving. Certificates orative, Inc. (MEC) and Neuro-
established and emerging work
practices. They will discuss amino will be mailed within 6-8 weeks Research. MEC is accredited as
of treating patients suffering
acid treatment results only following the activity. This activity a provider of continuing nursing
from master neurotransmitter
dreamed of in the past. We invite has been planned and imple- education by the American
dysfunctions. Overall, the course
you to take the time to learn of mented in accordance with the Nurses Credentialing Center’s
content will strengthen the
this new approach at one of the Essential Areas and Policies of Commission on Accreditation.
 participant’s knowledge of
formal continuing medical educa- the Accreditation Council for Provider approved by the California
clinical care of neurotransmitter
tion events. Their approach has Continuing Medical Education Board of Registered Nursing,
dysfunction in patients.
been described as a “paradigm through the joint sponsorship of Provider Number CEP 12990, for
shift in medicine” at national Medical Education Collaborative, 9.2 contact hour(s). This program
medical conferences where their Inc. (MEC) and NeuroResearch. is co-sponsored by Medical
work has been presented. MEC is accredited by the ACCME Education Collaborative, Inc.
to provide continuing medical (MEC) and NeuroResearch.
education for physicians. Medical MEC is approved by the American
Education Collaborative desig- Psychological Association to
For conference times nates this educational activity sponsor continuing education
and dates, go to for a maximum of 7.75 category 1 for psychologists. MEC maintains
credits towards the AMA Physician’s responsibility for this program
www.NeuroSupport.com
Recognition Award. Each physician and its content. The course
should claim only those credits provides 7.75 hours of credit.
NeuroResearch Catalog Dec 20.ind5 5 12/20/06 12:46:17 PM
_I .
(cid:127) (cid:127) (cid:127) (cid:127)
The “68” Docs
Since NeuroResearch started working with Amino acid treatment is not intuitive. Proper For several years we have been saying,
clinics outside of our own, we have come to training is needed to master their use. “68” docs “Docs trained at a seminar are using 20 to 30
refer to a specific type of doctor as a “68” have virtually no chance of obtaining the full times more amino acids than those who have
doc. So, what does this mean? potential of using amino acids without training. not been trained. This means 20 to 30 times
At present, NeuroResearch has hundreds of more patients and 20 to 30 times more reve-
1. After reading information on our work,
well trained clinics from across the United nues.” The fact is, approximately 80% of the
the typical “68” doc becomes very
States using amino acids every month. The top patients seen in a medical practice could ben-
excited about our work and wants to
20% are treating over 100 patients a month. efit from amino acid therapy for neurotrans-
try amino acids.
We rarely see a “68” doc that treats more than mitter dysfunction. Attending a seminar is
2. The typical “68” doc does not take the 6 to 8 patients. Amino acid training can be a necessary in order to master proper treat-
time to receive proper training on how great practice builder. ment and management of patients.
to use the formulas. In the process, they
usually use 6 to 8 bottles of amino acids
a month, for 6 to 8 months (hence the we will send out a notice to “send in your flash

term “68” docs). Eventually, they move on drives”. When you send it in, NeuroResearch
will load your drive with the latest work.
and attempt another project. They never
Each flash drive is loaded with day 1 talks
fully realize the treatment potential of the (neurotransmitters and amino acids) and day 2
amino acids. talks (management of a high performance
clinical weight loss program) plus a Power-
3. “68” docs tend to put the cart before the Contains over 40 NeuroResearch seminar Point viewer.
horse. They tend to ask, “How can I try slide shows with voice narrative.
Call 877-626-2220 for details.
the amino acids to see if I want to attend
The recommended starting point in neurotrans-
a continuing medical education seminar?” mitter clinical education is a live interactive con- Cost is:
tinuing education seminar. Beyond this step is the - $100 for physicians who have attended a
4. The typical “68” doc runs into problems
repetitive training found in our “flash drive educa- NeuroResearch training seminar in the past.
from misuse of amino acids. They tend to tion” program. This will allow you to review at your - $250 for physicians who have not attended a
blame the problems on the amino acids. leisure. NeuroResearch seminar.
Each flash drive contains over 40 NeuroResearch
The real problem is lack of training and
slide shows with voice narrative. Each drive comes For more information. go to
improper positioning of patients. in a storage box with a prepaid postage sticker. In www.NeuroAssist.com
the future, as new research materials are added,
NeuroResearch Catalog Dec 20.ind6 6 12/20/06 12:46:35 PM
_I .
(cid:127) (cid:127) (cid:127) (cid:127)
WHAT TO DO IF YOUR AMINO ACIDS
Neurotransmitter Diseases
ARE NOT WORKING?
Depression Hyperactivity
Anxiety Claustrophobia and
NeuroResearch is a medical research company dedicated to providing
Panic attacks Other Phobias
AMA approved category I medical education to physicians and continuing
Insomnia Tension Headaches
education to clinical psychologists in the area of amino acids as applied to
neurotransmitters. We have been training physicians since 1999. Parkinsonism Chronic Pain
98% of the comments during technical support phone calls are positive. Bulimia Nocturnal Myoclonus
They attest to the effectiveness of amino acid therapy. Approximately 2% Anorexia Irritable Bowel Syndrome/
of the calls are from physicians complaining that the amino acids are not
Premenstrual syndrome Crohn’s Disease
working in treatment. In reviewing these phone complaints, the following
Menopause Deterioration of Cognitive
problem appears to exist. In most cases, the calls are from physicians who
Obsessive Compulsive Functions with Aging
have received no formal training on how to properly use the amino acids.
Two major problems stem Disorder (OCD) Deterioration of Organ
from attempting to use amino Impulsivity System Innervation.
acids without formal training. Obsessionality Hormone Dysfunction
 First, the amino acid dosing is
Inappropriate Aggression Problems in Systems
typically improperly adjusted.
Inappropriate Anger Innervated by the
Secondly, often neurotrans-
Fibromyalgia Serotonin and/or
mitter lab tests are not
ordered at the correct time. Chronic Fatigue Syndrome Catecholamine Systems.
Attending our AMA approved Adrenal Fatigue/Burnout Cortisol Dysfunction
continuing education semi- Dementia Problems.
nars provides the training
Alzheimer’s Disease Neurotransmitter Reaction
needed to achieve positive
Traumatic Brain Injury to Chronic Stress.
results. Amino acid therapy
Psychotic Illness Obesity
guided with lab testing is a
powerful tool, but it only Migraine Headaches Restless Leg Syndrome
works when you understand ADHD/ADD
how to use it.
The only way for this powerful tool to achieve its full potential in your hands is
to first obtain proper training at one of our AMA approved continuing medical
education seminars.
NeuroResearch Catalog Dec 20.ind7 7 12/20/06 12:46:53 PM
_I .
(cid:127) (cid:127) (cid:127) (cid:127)
ON/OFF:
When treating patients with diseases caused by or associated with the master
neurotransmitters, the starting point of treatment is to use the protocols found
on page 9. 70 to 80% of patients will achieve relief of symptoms by the time the
level 3 amino acid dosing is in place for one week. For the remaining 20 to 30%
of patients, relief of symptoms requires the guidance of urinary neurotransmitter
testing to properly adjust the amino acid dosing. Most patients do not need
urinary serotonin and dopamine levels fully established in the therapeutic range
and in the Phase 3 Response™ in order to obtain relief of symptoms. Once relief
of symptoms is obtained, no further testing is needed and amino acids do not
need further adjustments (unless symptoms return).
The response to amino acids is like a light switch. It is either on (relief of
symptoms obtained) or off (relief of symptoms is not obtained). In those patients
that need urinary neurotransmitter testing, continued testing and adjustments of
amino acid doses is needed until symptoms are resolved. If the phase 3 thera- 
peutic response is obtained and disease symptoms do not resolve, please call
NeuroResearch for a free consult with one of our licensed medical doctors.
Almost every week during telephone consults physicians say,
“I have been treating this patient for 6 weeks. I have done 3 urinary neurotrans-
mitters tests. The patient is not better. Should I keep trying to treat this pa-
tient?” The answer to the question is, “yes”. Most patients who need neurotrans-
mitter testing will obtain relief of symptoms by the time the third urinary test is
obtained. However, there are examples of patients who need an atypical amino
acid dosing. The response to amino acids is like a light switch, it is either on or
off. In those patients that need urinary neurotransmitter testing, and adjusting
the amino acid dosing should be continued until the light switch comes on and
symptoms resolve. With the aid of urinary neurotransmitter testing to adjust
amino acid doses, difficult to treat patients will eventually obtain relief of
symptoms.
NeuroResearch Catalog Dec 20.ind8 8 12/20/06 12:47:23 PM
_I .
(cid:127) (cid:127) (cid:127) (cid:127)
Important Points of Treatment
5-HTP/Tyrosine TreATMenT ProToCoL
n Start all adult patients on the level 1 dosing. Cysteine Generic Protocol Presented in Seminar (Cofactors also needed)
and selenium should be divided into three equal doses with
the first dose taken at noon. AM NOON 4 PM 7 PM
n When patients return to the clinic after one week, the LEvEL 1 150/1,500 --- 150/1,500 ---
question to ask is not, “How did you feel this week?”
The question should be, “How did you feel yesterday?” LEvEL 2 150/1,500 150/1,500 300/1,000 ---
It takes 3 to 5 days to get a complete response when
starting or changing an amino acid dose. How the patient LEvEL 3 150/1,500 150/1,500 300/1,000 300/1,000
did yesterday is more indicative of the clinical response to
amino acids than asking about the entire week. PER DOSE (Milligrams 5-HTP / Milligrams tyrosine)
n Read the “side effects section” of this booklet starting on If the patient’s symptoms remain at level 3, obtain a urinary neurotransmitter test.
page 30.
All patients need to take a total of 4,500 mg of cysteine with selenium
n If you are experiencing problems with side effects or are
and folate per day. The cysteine, selenium and folate formula should be
not getting the outcomes that we claim, call NeuroResearch
taken in equally divided doses with the first dose at noon.
at 877-626-2220. Our technical support staff will be glad
 to answer any questions.
5-HTP/Tyrosine wiTH L-doPA TreATMenT ProToCoL
Generic Protocol Presented in Seminar (Cofactors also needed)
The only way for Recommended only for treatment of obesity, Parkinsonism,
and Restless Leg Syndrome.
this powerful tool to
achieve its full potential AM NOON 4 PM 7 PM
in your hands is to first
LEvEL 1 150/1,500/60 --- 150/1,500/60 ---
obtain proper train-
ing at one of our AMA LEvEL 2 150/1,500/60 150/1,500/60 300/1,000/60 ---
approved continuing
LEvEL 3 150/1,500/60 150/1,500/60 300/1,000/60 300/1,000/60
medical education
seminars.
PER DOSE (Milligrams 5-HTP / Milligrams tyrosine / Milligrams L-dopa)
(see page 5.) If the patient’s symptoms remain at level 3, obtain a urinary neurotransmitter test.
All patients need to take a total of 4,500 mg of cysteine with selenium
and folate per day. The cysteine, selenium and folate formula should be
taken in equally divided doses with the first dose at noon.
NeuroResearch Catalog Dec 20.ind9 9 12/20/06 12:47:52 PM